Digital Diagnostics Inc.

Digital Diagnostics Inc. is a clinical software company specializing in FDA-cleared artificial intelligence platforms for autonomous medical diagnosis. The company's flagship product, LumineticsCore®, is an FDA-cleared AI diagnostic system that identifies diabetic retinopathy at the point-of-care using fundus imaging analysis, capable of providing diagnosis within 30 seconds without requiring physician interpretation. LumineticsCore integrates with electronic health record systems (EPIC) and is reimbursable via CPT code 92229, enabling primary care and community health settings to perform diabetic eye examinations and close HEDIS quality care gaps. The company serves healthcare systems, primary care clinics, community health centers, and urgent care facilities nationwide, with documented real-world evidence demonstrating increased screening adherence, improved referral follow-up rates, and enhanced provider efficiency. Digital Diagnostics is actively researching additional ophthalmologic and systemic disease applications including glaucoma, age-related macular degeneration, cardiovascular indications, and neurodegenerative conditions detectable via retinal imaging. The company emphasizes health equity, regulatory compliance, and evidence-based outcomes through peer-reviewed publications and case studies from institutions including Stanford Health System, Johns Creek Primary Care, Tarzana Treatment Centers, and Cahaba Medical Care.